Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits

Kevin Beccaria, MD,1,2 Michael Canney, PhD,1 Lauriane Goldwirt, PharmD, PhD,3 Christine Fernandez, PharmD, PhD,3 Julie Piquet, MS,4 Marie-Cécile Perier, MSc,5 Cyril Lafon, PhD,6 Jean-Yves Chapelon, PhD,6 and Alexandre Carpentier, MD, PhD7,8

1 CarThera Research Team, Brain and Spine Institute, Paris; 2 Department of Neurosurgery, Assistance Publique–Hôpitaux de Paris, Necker Enfants Malades Hospital, Paris; 3 Clinical Pharmacy Department, College of Pharmacy, Paris Sud University, Chatenay Malabry; 4 Laboratory of Biosurgical Research, University of Paris Descartes, Sorbonne Paris Cite, Paris; 5 INSERM U970, Centre de recherche cardiovasculaire de Paris–Épidémiologie cardiovasculaire, Paris; 6 INSERM U1032, LabTau, University of Lyon; 7 Assistance Publique–Hôpitaux de Paris, Pitié Salpetrière Hospital, Department of Neurosurgery, Paris; and 8 Paris 6 Sorbonne University, School of Medicine, Paris, France

OBJECTIVE The blood-brain barrier (BBB) limits the intracerebral penetration of drugs and brain tumor treatment efficacy. The effect of ultrasound-induced BBB opening on the intracerebral concentration of temozolomide (TMZ) and irinotecan (CPT-11) was assessed.

METHODS This study was performed using 34 healthy New Zealand rabbits. Half had unilateral BBB opening, and half served as controls. Sonications were performed by pulsing a 1.05-MHz planar ultrasound transducer with a duty cycle of 2.5% and an in situ acoustic pressure level of 0.6 MPa after injection of a microbubble ultrasound contrast agent. Drugs were injected either 5 minutes before (ChemoPreUS) or 15 minutes after (ChemoPostUS) the ultrasound sonication. The plasma and intracerebral concentrations of both drugs were quantified using ultra-performance liquid chromatography.

RESULTS The mean intracerebral tissue-to-plasma drug concentration ratio in the control hemispheres was 34% for TMZ and 2% for CPT-11. After BBB opening, these values increased by up to 21% for TMZ and up to 178% for CPT-11. Intracerebral concentrations of drugs were enhanced in regions where the BBB was opened compared with the contralateral hemisphere (p < 0.01 and p < 0.0001 for CPT-11, p = 0.02 and p = 0.03 for TMZ, in ChemoPreUS and ChemoPostUS, respectively) and compared with the control group (p < 0.001 and p < 0.0001 for CPT-11, p < 0.01 and p = 0.02 for TMZ, in ChemoPreUS and ChemoPostUS, respectively). The intracerebral distribution of drugs was heterogeneous, depending on the distance from the ultrasound source.

CONCLUSIONS Ultrasound-induced opening of the BBB significantly enhances the intracerebral concentration of both TMZ and CPT-11 in rabbits.

http://thejns.org/doi/abs/10.3171/2015.4.JNS142893

KEY WORDS blood-brain barrier; brain tumors; drug delivery; irinotecan; oncology; temozolomide; ultrasound
Although several methods have been proposed to increase the permeability of the BBB, pulsed ultrasound is one that has shown significant promise in laboratory studies conducted over the past decade. Using a pulsed ultrasound source in combination with an ultrasound contrast agent (UCA), the application of low-power sonication on brain parenchyma can safely and temporarily open the BBB for durations of 6–8 hours. Mechanisms of opening the BBB by pulsed ultrasound may include transcytosis, transendothelial opening with cell fenestrations, and opening of tight junctions. All of these mechanisms may potentially allow for increased passage of drug molecules.

An improved uptake of drugs into the brain after ultrasound-induced BBB disruption has been demonstrated for antineoplastic drugs, such as doxorubicin, cisplatin, and bis(2-chloroethyl)-1-nitrosourea (BCNU). In addition to high-molecular-weight antibodies, such as trastuzumab, dopamine receptor antibodies, and anti-β-amyloid antibodies, increased drug delivery to the brain is associated with tumor control and increased survival can be achieved. Although initial studies demonstrating safe BBB opening by pulsed ultrasound were performed in small-animal models, recent studies have confirmed these results in nonhuman primates.

The human skull represents the principle obstacle to the use of ultrasound in neurooncology, because ultrasound energy is attenuated and distorted by the skull bone. While transcranial ultrasound delivery into the brain is in clinical development for certain indications, the technique requires MRI monitoring, complicated electronics, and corrections for phase distortion and attenuation. Therefore, the technique may not be suited for repetitive BBB opening every month, which is required to optimize intravenous chemotherapy delivery for diffuse gliomas. Considering the fact that surgery is systematically performed for the treatment of primary brain tumors, either to resect the tumor (debulking surgery) or to remove a tissue sample for histological analysis (biopsy), a new implantable ultrasound device has been developed to take advantage of the skull bone opening. By implanting a small ultrasound device into the bone during these surgical procedures, distortion of the ultrasound energy can be avoided, and the procedure can be simplified. In a recent publication by our team, this concept was demonstrated, and a planar ultrasound device has been developed to take advantage of the skull bone opening. By implanting a small ultrasound device, monitoring of BBB opening using Evans blue dye of the ultrasound sonication. Additional details about the device, monitoring of BBB opening using Evans blue dye diffusion, and MRI are described in a previous publication.

**Methods**

**Preparation of Animals**

All of the animal experiments were approved by a local ethics committee (Comité d’Éthique en matière d’Expérimentation Animale, Paris-Descartes, France). This study was performed using 34 healthy male New Zealand white rabbits. Animals were anesthetized with an intramuscular injection of a mixture of xylazine (9 mg/kg; Rompun, 2% solution, Bayer) and ketamine (50 mg/kg; Imalgène, solution of 1000 mg/10 ml, Merial). Additional injections were performed during the experiments if necessary. A femoral vein was catheterized for perfusion of isotonic saline, drugs, and UCA. Analgesia was ensured with 1.5 ml of lidocaine (Xylocaine 1%, scalp infiltration) and intravenous (IV) bolus of morphine (Mor- phine Lavoisier, 10 mg/ml). A bur hole craniectomy was unilaterally performed from the coronal suture to 12 mm posteriorly. Euthanization of the animals was performed by IV injection of pentobarbital sodium salt (54.7 mg/100 ml). Brains were extracted at the end of each experiment and immediately frozen (−20°C). A blood sample was harvested 5 minutes before each animal was humanely killed. Plasma was extracted from the blood sample by centrifugation and frozen (−20°C).

**Ultrasound Experimental Setup**

A custom-built, air-backed, 1-MHz single-element transducer was constructed by using a 10-mm flat piezoceramic disc (Pz 26, Ferroperm Piezocermics). The transducer was operated at a center frequency of 1.05 MHz and a pulse repetition frequency of 1 Hz, with a pulse length of 25,000 cycles (2.5% duty cycle, 23.2 msec total burst duration) and an in situ acoustic pressure level of 0.6 MPa. These parameters correspond to safe parameters for BBB opening that were determined in a previous study. For each session of BBB opening, a bolus injection of microbubbles (Sonovue, 0.1 ml/kg, Bracco Imaging) was injected through a peripheral vein followed by a 2-ml flush of saline. Sonovue is a UCA made of sulfur hexafluoride gas enveloped in a phospholipid shell with a mean diameter of 2.5 μm. The total sonication duration was 2 minutes. Microbubbles were injected at the same time as the start of the ultrasound sonication. Additional details about the device, monitoring of BBB opening using Evans blue dye diffusion, and MRI are described in a previous publication.

**Drug Injection Protocols**

For both drugs, 2 experimental protocols were used in this study (Fig. 1). In each protocol, the time of reference (T0) corresponded to the beginning of the ultrasound sonication in the presence of the UCA. In the first protocol (ChemoPreUS, n = 16), the drug was injected 5 minutes before sonication (T-5 min). Blood samples were taken at 25 minutes (T+25 min), and animal euthanization was performed at 30 minutes (T+30 min) after sonication. In the second protocol (ChemoPostUS, n = 18), the drug was injected 15 minutes after sonication (T+15 min). Blood samples were taken at 40 minutes (T+40 min), and animal euthanization was performed at 45 minutes (T+45 min).
min) after sonication. In each protocol, the drug circulated for 30 minutes after BBB opening. Considering the half-lives of TMZ and CPT-11, and taking into account the fact that the brain/plasma concentration ratio of both drugs is stable during their distribution, this delay was adapted to highlight any drug enhancement. Moreover, it corresponded to a previously published protocol.

CPT-11 was injected intravenously at a dose of 6 mg/kg (Irinotecan Ebewe Pharma France, Sandoz 40 mg/2 ml) and TMZ at a mean dose of 4.7 mg/kg, corresponding to a dose of 75 mg/m$^2$ of body surface, with $S = (K \times P^{2/3})/10^4$, in which $P$ represents the weight of the animal and $K = 9.5$. These doses corresponded to doses used in clinical practice.

For each experimental protocol group, half of the rabbits ($n = 17$) underwent sonication on a region of the right hemisphere after craniotomy and in the presence of Sonovue. The other half ($n = 17$) served as controls and received only a right bur hole craniotomy, without sonication and without Sonovue injection.

Quantification of TMZ and CPT-11

A slice of brain parenchyma, centered along the acoustic axis of the ultrasound transducer, was cut from each rabbit brain. Four representative samples (450 mg each) were extracted from each slice: a cortical and a deep brain sample from each hemisphere (Fig. 2). A number was attributed to each sample for further blinded analysis. Chromatography was performed on an Acquity UPLC system (Waters Corp.) with an autosampler temperature of 6°C. Separation was performed at 25°C on a Waters Acquity UPLC BEH C18 column (2.1 mm × 100 mm, 1.7-µm particle size) with a linear gradient elution using water (containing 0.1% formic acid and 10 mM ammonium acetate) and acetonitrile as the mobile phase.

TMZ and CPT-11 quantification in plasma and brain was performed following previously published methods using ultra-performance liquid chromatography with tandem mass spectrometry detection.

Statistical Analysis

Statistical analysis was performed using the R Project (version 3.0.2). Parenchyma concentrations were systematically divided by the corresponding plasma concentration to obtain a ratio of concentration, expressed as a percentage. All comparisons were performed with the concentration ratios. Data are summarized using mean (SD) values. Comparisons of drug concentration ratios between the group that underwent sonication and the control group were performed using the Student t-test. Within each group, the diffusion ratio between sonicated hemispheres and nonsonicated hemispheres were compared using the paired Student t-test. For all analyses, a 2-tailed $p$ value < 0.05 was considered statistically significant.

Results

This study was performed using a total of 34 rabbits. Fourteen rabbits received TMZ, 8 in the ChemoPreUS protocol and 6 in the ChemoPostUS protocol. Twenty rabbits received CPT-11, 8 in the ChemoPreUS protocol and 12 in the ChemoPostUS protocol. Mean plasma and brain parenchyma concentrations and corresponding concentration ratios for both protocols are reported in Table 1.

Ultrasound-Induced Opening of the BBB and Drug Delivery to the Brain

For TMZ, the mean concentration ratio (brain/plasma) in sonicated hemispheres was significantly higher than the mean concentration ratio in nonsonicated contralateral hemispheres (Fig. 3 upper), for both the ChemoPreUS (41.4% vs 34.7%, respectively; $p < 0.001$) and Chemo-
Ultrasound-induced opening of the BBB for drug delivery

For CPT-11, the mean concentration ratio (brain/plasma) in sonicated hemispheres was significantly higher than the mean concentration ratio in nonsonicated contralateral hemispheres (Fig. 3 lower), for both the ChemoPreUS (6.1% vs 2.9%, respectively; p = 0.02) and ChemoPostUS (6.8% vs 2.1%, respectively; p < 0.001) protocols.

Concentration Enhancement of TMZ in the Brain and Depth of Sonication

For TMZ, the mean concentration ratio within the cortex varied from 36% to 38% in nonsonicated cortex and was 45% in sonicated cortex of rabbits that underwent sonication in the ChemoPreUS protocol (p = 0.04, comparison between both hemispheres in rabbits that underwent sonication; p = 0.02, comparison between sonicated cortex of rabbits that underwent sonication and nonsonicated cortex of control rabbits). The mean concentration ratios varied from 35% to 42% in nonsonicated cortex and was 48% in sonicated cortex in the ChemoPostUS protocol (p = 0.07, comparison between both hemispheres in rabbits that underwent sonication; p = 0.03, comparison between sonicated cortex of rabbits that underwent sonication and nonsonicated cortex of control rabbits). In the deep brain

### TABLE 1. Mean plasma and brain parenchyma concentrations and corresponding concentration ratios for ChemoPreUS and ChemoPostUS protocols

<table>
<thead>
<tr>
<th>Protocol Group</th>
<th>Protocol</th>
<th>Group</th>
<th>TMZ Concentration (n = 14)</th>
<th>CPT-11 Concentration (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plasma (ng/ml)</td>
<td>Brain (ng/g)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>US hemisphere</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cortex</td>
<td>3999 ± 628</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deep brain</td>
<td>1493 ± 255</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-US hemisphere</td>
<td>1421 ± 260</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deep brain</td>
<td>1357 ± 261</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-US hemisphere</td>
<td>4135 ± 242</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-US hemisphere</td>
<td>1274 ± 121</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cortex</td>
<td>1575 ± 97</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deep brain</td>
<td>1239 ± 97</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nonsonicated controls†</td>
<td>3426 ± 179</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>US hemisphere</td>
<td>1320 ± 63</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cortex</td>
<td>1331 ± 115</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deep brain</td>
<td>1197 ± 72</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-US hemisphere</td>
<td>3947 ± 213</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-US hemisphere</td>
<td>1305 ± 127</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cortex</td>
<td>1652 ± 217</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deep brain</td>
<td>1216 ± 60</td>
</tr>
</tbody>
</table>

US = ultrasound.

* Values given as mean ± SD unless otherwise indicated.
† Nonsonicated control rabbits have 2 hemispheres; therefore deep brain and cortex are listed twice.

PostUS (43.1% vs 36.9%, respectively; p = 0.03) protocols. This significant difference was also confirmed when the sonicated hemispheres of rabbits that had undergone sonication were compared with the same hemispheres in control rabbits that received no ultrasound, for both the ChemoPreUS (41.4% vs 33% respectively; p < 0.01) and ChemoPostUS (43.1% vs 34.1% respectively; p = 0.02) protocols.

For CPT-11, the mean concentration ratio (brain/plasma) in sonicated hemispheres was significantly higher than the mean concentration ratio in nonsonicated contralateral hemispheres (Fig. 3 lower), for both the ChemoPreUS (6.1% vs 2.9%, respectively; p = 0.02) and ChemoPostUS (6.8% vs 2.1%, respectively; p < 0.001) protocols. This significant difference was also confirmed when the sonicated hemispheres of rabbits that underwent sonication were compared with the same hemispheres in control rabbits that received no ultrasound, for both the ChemoPreUS (6.1% vs 2%, respectively; p < 0.001) and ChemoPostUS (6.8% vs 2.8%, respectively; p < 0.0001) protocols.
parenchyma, the TMZ concentration ratio of the rabbit group that underwent sonication was statistically different between sonicated and nonsonicated contralateral deep brain parenchyma only for the ChemoPreUS protocol ($p = 0.01$) and not for the ChemoPostUS protocol ($p = 0.15$). When comparing the TMZ concentration of sonicated deep brain parenchyma with rabbits that did not undergo sonication (controls), a statistically significant difference appeared in ChemoPreUS (37% vs 31%, respectively; $p = 0.02$), which was not observed in the ChemoPostUS (39% vs 33%, respectively; $p = 0.2$).

For CPT-11, no significant statistical difference was observed in concentration ratios when sonicated and nonsonicated cortex of rabbits that underwent sonication were compared in the ChemoPreUS protocol (7% versus 2%, respectively, $p = 0.06$). In all other cases, the mean concentration ratios were significantly higher in both sonicated cortex and deep brain parenchyma in both ChemoPreUS and ChemoPostUS protocols. The mean ratio was 7% in sonicated cortex while varying from 2% to 3% in nonsonicated cortex in both ChemoPreUS and ChemoPostUS. The mean ratio varied from 5% to 7% in sonicated deep brain parenchyma, while it varied from 2% to 3% in nonsonicated deep brain parenchyma in both ChemoPreUS and ChemoPostUS.

Reliability of the Experimental Model

No statistical differences were observed in the concentration of TMZ and CPT-11 when comparing both hemispheres of rabbits that did not undergo sonication (controls). This observation was true for both cortex and deep brain parenchyma, in both ChemoPreUS and ChemoPostUS. No difference was observed either between nonsonicated contralateral hemispheres of rabbits that underwent sonication and hemispheres of rabbits that did not (controls). Ratios of concentration varied from 30% to

---

**FIG. 3.** TMZ (upper) and CPT-11 (lower) concentration ratios (brain/plasma) for the ChemoPreUS (left) and ChemoPostUS (right) protocols. Contralateral = nonsonicated hemispheres of rabbits that underwent sonication. Control = both hemispheres of rabbits that did not undergo sonication. Sonicated = sonicated hemispheres of rabbits that underwent sonication. Data points for the cortex (triangles) and deep brain (circles) as well as statistical significance are indicated (*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$).
42% for TMZ and from 2% to 3% for CPT-11. One exception was observed when penetration of TMZ was compared in the cortex of nonsonicated hemispheres of rabbits that underwent sonication with those that did not (controls) for ChemoPreUS (p = 0.02).

Comparison Between Mean Enhancement of CPT-11 and Mean Enhancement of TMZ After Sonication

In protocol ChemoPreUS, the mean concentration ratio of TMZ was 34% in the brain parenchyma of control rabbits, 35% in the nonsonicated hemispheres of rabbits that underwent sonication, and 6% in sonicated hemispheres of rabbits that underwent sonication. In protocol ChemoPostUS, mean values were 35%, 37%, and 43%, respectively. Thus, the mean delivery enhancement of TMZ after sonication was 21% and 19% in ChemoPreUS and ChemoPostUS protocols, respectively.

In protocol ChemoPreUS, the mean concentration ratio of CPT-11 was 2% in brain parenchyma of control rabbits, 2.5% in the nonsonicated hemispheres of rabbits that underwent sonication, and 6% in sonicated hemispheres of rabbits that underwent sonication. In protocol ChemoPostUS, mean values were 3%, 2%, and 7%, respectively. Thus, the mean delivery enhancement of CPT-11 after sonication was 178% and 162% in ChemoPreUS and ChemoPostUS protocols, respectively.

The mean enhancement ratio was not significantly different between ChemoPreUS and ChemoPostUS for both CPT-11 (p = 0.50) and TMZ (p = 0.62).

Discussion

Contrary to many previous studies published in the literature that use external focused ultrasound devices, the implantable unfocused ultrasound device currently being developed—and which has an identical acoustic field to the version used in these studies—is particularly adapted to be easy to use for repetitive clinical treatments. The device is designed to be implanted in a 12-mm skull bur hole, a size that is commonly used during craniotomies, either immediately following resection of the tumor or during a unique surgical procedure. The device is activated on demand during repeated chemotherapy sessions by connecting a transcutaneous needle that has been developed to plug into the implant. Activation is performed in a procedure that lasts approximately 15 minutes and which a skilled nurse can perform. In addition, the device has been designed to be compatible with MRI, which allows for monitoring of treatment follow-up.

The use of unfocused ultrasound allows for sonication of a large volume of brain parenchyma, corresponding to the size of brain tumors or surgical cavities after tumor removal. It was observed in a previous publication that opening of the BBB could be performed in regions where the in situ acoustic pressure was less than half that of the acoustic pressure applied along the acoustic axis. This corresponded to volumes of almost 2 cm³ (2.5-cm high cylinder with a radius of 0.5 cm) with a transducer of 1 cm in diameter. In contrast, focused ultrasound systems have a small focal volume (3 x 6 mm) and therefore must be electronically steered or mechanically scanned to disrupt the BBB in larger volumes. For example, McDannold et al. used a focused transcranial ultrasound system and performed sonications over 9 treatment points with a spacing of 2 mm to disrupt the BBB in a volume of tissue of 1 cm³. Scanning of the focus over a larger volume using such devices is possible, but potentially increases the procedure time and leads to additional uncertainty in the acoustic pressure at the focus.

While there have been no previous studies on the diffusion of CPT-11 after ultrasound-induced opening of the BBB, Wei et al. recently assessed the therapeutic effect of TMZ in association with ultrasound-induced opening of the BBB on rats implanted with 9L glioma cells. In their study, they observed that the TMZ CSF/plasma ratio was increased from 22.7% to 32.6% due to ultrasound exposures, while the 7-day tumor progression ratio was reduced from 24 to 5 days and median survival was extended from 20 to 23 days.

The mean concentration ratio observed in the current study (varying from 30% to 42%, Table 1) was on the same order of magnitude as the ratio reported by Wei et al. (CSF/plasma ratio of 22.7%). The ratio observed in this study of 3% for CPT-11 was significantly lower. These results imply that both drugs spontaneously can pass the intact BBB but with a very low rate, and with a better passage for TMZ than for CPT-11. This is in accordance with the partial and transient efficiency of these drugs on brain tumors and the better results obtained with TMZ than with CPT-11. In addition, both clinical and experimental observations confirm that the use of high doses of both TMZ and CPT-11 increase their antitumoral activity. For both TMZ and CPT-11, the main limit to high-dose protocols remains the systemic side effects of these drugs. In this context, ultrasound-induced opening of the BBB appears to be an ideal technique that may enhance drug delivery to the brain without having to increase the amount of systemically administered drug.

Penetration of drug was heterogeneous when taking into account the depth of sonication in the brain parenchyma. While the few number of cases studied in this work may partially explain such a result, this observation is also in accordance with previously published studies in which opening of the BBB was more intense in the gray matter than in the white matter. It has been hypothesized that this difference is due to a more dense vasculature network in the cortex (gray matter) than in the deep brain parenchyma (mix of white and gray matter), causing the surface of exchange between blood circulation and brain parenchyma to be higher in the gray matter. This will need to be taken into consideration in future clinical applications.

No significant differences were observed between concentration ratios in the ChemoPreUS and ChemoPostUS protocols, so that the time of injection, before or after sonication, did not have any influence on drug passage through the BBB. The consequence in clinical practice is that the time of injection can be adapted to drugs, depending on their pharmacological and pharmacodynamic characteristics. Injection may be performed before the sonication if the direct effect of ultrasound on the drug may increase local delivery, for example with encapsulated drugs that would be liberated when entering the ultrasound field.
Alternatively, in the case of delicate molecules, injection after sonication may be better, because it avoids the mechanical effects of ultrasound on the drug molecule.

While enhanced tumor control was not shown in our study, many others have shown that enhanced penetration of chemotherapeutics after BBB opening can have significant effects on tumor growth and survival in animal models. For example, doxorubicin delivery was studied by Treat et al. who were able to enhance the doxorubicin concentration in rat brain up to therapeutic levels. This corresponded to a 3.5-fold enhancement (about 252% enhancement), and it was associated with minimal vascular effects and no macroscopic tissue damage. Even further enhancement was also possible (up to 23.5-fold the control concentration) but was associated with severe tissue damage and neuronal death. The same authors showed that enhanced delivery of liposomal doxorubicin reduced tumor growth and increased survival in rats inoculated with gliosarcoma cells in the brain. Liu et al. also demonstrated antitumoral effects of ultrasound-induced BBB opening with BCNU on rats implanted with C6 glioma cells. Treatments resulted in control of tumor progression and significantly increased animal survival compared with rats treated by ultrasound or BCNU alone. Tumor control and increased survival were also observed in studies using BCNU encapsulated in microbubbles. The pegylated capsules used in the study not only protected BCNU from rapid hydrolysis, but also reduced drug exposure and toxicity to other normal tissues, particularly the liver.

Both clinical and experimental observations have confirmed that the use of high doses of both TMZ and CPT-11 increase their antitumoral activity. On one hand, removal of O-6-methylguanidine by the DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT) promotes resistance to TMZ in human glioma cell lines, but it has been hypothesized that high doses of TMZ may induce MGMT saturation and overcome this resistance. Such a saturation of MGMT would explain the longer survival obtained with protracted and continuous schedules in humans or with increased local brain delivery of TMZ by biodegradable polymers in a rodent glioma model. On the other hand, Jiang et al. have recently shown that high doses of CPT-11 may increase the in vivo inhibition of U87 tumor growth in nude mice models.

In the same way, some studies suggest that a modest enhancement of either TMZ or CPT-11 may be sufficient to obtain a significant improvement in their antitumoral activity. The 170% increase in CPT-11 brain distribution after BBB opening that was observed in our study is clinically relevant considering previous studies. Verrecault et al. showed that using a liposomal formulation of CPT-11 provided a 25% increase in CPT-11 in the brain and led to a significant increase in average survival (63.1 vs 58.3 days, after liposomal and normal formulation administration, respectively). It has also been demonstrated that TMZ and CPT-11 are drug efflux transporter ABCB1 (P-glycoprotein) substrates that have been associated with higher TMZ and CPT-11 brain distribution in ABCB1-deficient mice. Interestingly, the amount of increase in brain-to-blood ratios obtained after BBB opening (1.37-fold and 2.70-fold higher after ultrasound for TMZ and CPT-11, respectively) were close to those obtained in ABCB1-deficient mice (1.1 and 2.1 for TMZ and CPT-11, respectively), suggesting that BBB opening reverses the effects of ABCB1 on drug brain distribution, which is of great interest in brain tumor treatment.

Conclusions

The BBB constitutes a major impediment to drug delivery to the brain in the treatment of primitive brain tumors, and it is now well known that low-power pulsed ultrasound can open the BBB in a safe and reversible manner. In the present work, it has been demonstrated that both TMZ and CPT-11 delivery into the brain parenchyma could be enhanced after opening of the BBB by an unfocused ultrasound device in the presence of microbubble agents. By using a transducer that can be plugged into the skull at the end of a regular procedure (biopsy/debulking), such a technique may allow oncologists to repeatedly and transiently open the BBB at the time of drug administration. Drug delivery to the brain and tumoral tissue could be improved while systemic doses could be decreased to reduce side effects and the subsequent morbidity of chemotherapy.

Acknowledgments

CarThera and the Paris Regional Innovation Center supported this work. We gratefully acknowledge Alain Birer, Adrien Matias, and Alexandre Vignot for help with the design and construction of transducers and the experimental setup. We also gratefully acknowledge all members of the team of the Laboratory of Biosurgical Research, Paris, France, and its director Professor Philippe Menasché, for their help in the realization of animal experiments.

References

8. Fortin D: The blood-brain barrier should not be underesti-
Ultrasound-induced opening of the BBB for drug delivery


Disclosures
Alexandre Carpentier, Kevin Beccaria, Michael Canney, Cyril Lafon, and Jean-Yves Chapelon have submitted a patent application on this technology and licensed it to CarThera. Alexandre Carpentier, Michael Canney, Cyril Lafon, and Jean-Yves Chapelon have ownership in CarThera SAS, a spin-off start-up company from Paris VI Sorbonne University. Michael Canney is an employee of CarThera SAS. Kevin Beccaria’s research was supported by CarThera SAS.

Author Contributions
Conception and design: Carpentier, Beccaria, Canney, Fernandez, Lafon, Chapelon. Acquisition of data: Beccaria, Canney, Goldwirt, Piquet. Analysis and interpretation of data: Carpentier, Beccaria, Canney, Goldwirt, Fernandez, Lafon, Chapelon. Drafting the article: Carpentier. Critically revising the article: Carpentier, Beccaria, Canney, Goldwirt, Fernandez, Lafon, Chapelon. Reviewed submitted version of manuscript: Carpentier, Beccaria, Canney, Goldwirt, Fernandez, Lafon, Chapelon. Approved the final version of the manuscript on behalf of all authors: Carpentier. Statistical analysis: Beccaria, Canney, Perier. Study supervision: Carpentier.

Supplemental Information
Previous Presentation
 Portions of this work were presented in poster form at the IEEE-UFFC Symposium, Prague, Czech Republic, July 25, 2013, and as an oral presentation at the 13th International Symposium on Therapeutic Ultrasound, May 13, 2013.

Correspondence
Alexandre Carpentier, Department of Neurosurgery, Pitie-Salpétrière Hospital, Assistance Publique Hôpitaux de Paris, Sorbonne University, Paris 6 School of Medicine, Paris 75013, France. email: alexandre.carpentier@psl.aphp.fr.